Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Colorectal Neoplasms 50Stomach Neoplasms 13Colonic Neoplasms 5Rectal Neoplasms 4Sarcoma 3Neoplasms 2Neoplasm Metastasis 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Hepatocellular 2Advanced Colorectal Carcinoma 2Unresectable Metastatic Colorectal Cancer 1To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1TAS 102 1Sarcoma, Ewing 1Platinum Resistant Ovarian Cancer 1Patients With Advanced Metastatic Colorectal Cancer 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm, Residual 1Metastatic Colorectal Adenocarcinoma 1Metastasis Colorectal Cancer 1Locally Advanced Rectal Cancer 1HER2-positive Gastric Cancer 1Gastric Cancer Adenocarcinoma Metastatic 1Fruquintinib 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Cancer Metastatic 1Colorectal Adenocarcinoma 1Carcinoma, Renal Cell 1

Interventions

Methotrexate 21Ifosfamide 21Cyclophosphamide 19Doxorubicin 17Cisplatin 14Filgrastim 13Gemcitabine 12Etoposide 11Leucovorin 9apatinib 8fludarabine 7glucarpidase 6Vincristine 6Temozolomide 6Radiotherapy 6Nivolumab 6Neoadjuvant Therapy 6Drug Therapy 6Carboplatin 6regorafenib 5cabozantinib 5Zoledronic Acid 5Topotecan 5Mesna 5Irinotecan 5Granulocyte Colony-Stimulating Factor 5Docetaxel 5pembrolizumab 4pegfilgrastim 4camrelizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Osteosarcoma × HMPL-013 × Clear all
NCT06202599 2024-01-17

Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance

Peking University People's Hospital

Completed
124 enrolled
Sarcoma

Bone Neoplasms, Neoplasms, Sarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡